<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002533</url>
  </required_header>
  <id_info>
    <org_study_id>19920577</org_study_id>
    <secondary_id>CDR0000078457</secondary_id>
    <secondary_id>NCI-V93-0288</secondary_id>
    <secondary_id>SCCC-1992110</secondary_id>
    <nct_id>NCT00002533</nct_id>
  </id_info>
  <brief_title>Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer</brief_title>
  <official_title>A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving fluconazole may be effective in preventing or controlling mucositis caused
      by radiation therapy to the head and neck.

      PURPOSE: Randomized phase II/III trial to study the effectiveness of fluconazole in
      preventing mucositis in patients undergoing radiation therapy for head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the effect of prophylactic antifungal therapy with fluconazole on the
           incidence and severity of radiation-associated mucositis/thrush in patients with head
           and neck cancer undergoing definitive radiotherapy.

      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients undergo standard hyperfractionated radiotherapy 5 days a week for 5-5.6
           weeks. Patients receive oral fluconazole on days 1-4 and 28-31 of radiotherapy.

        -  Arm II: Patients undergo radiotherapy as in arm I. Patients who develop a
           microbiologically proven fungal infection or clinically evident oral cavity and/or
           oropharyngeal thrush may receive fluconazole as in arm I.

      PROJECTED ACCRUAL: At least 42 patients (26 per arm) will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1993</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <condition>Infection</condition>
  <condition>Oral Complications</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven head and neck cancer undergoing definitive radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 21

        Performance status:

          -  Karnofsky 70-100%

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  SGOT and SGPT less than 2 times normal

          -  Alkaline phosphatase less than 2 times normal

        Renal:

          -  Not specified

        Other:

          -  No history of hypersensitivity to fluconazole

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  At least 2 months since prior antifungal agents

          -  Not currently receiving phenytoin, hydrochlorothiazide, or warfarin

               -  If these medications are initiated during study therapy, medication serum levels
                  and electrolytes are monitored for possibility of drug interaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold M. Markoe, MD, ScD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sylvester Cancer Center, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2003</study_first_posted>
  <last_update_submitted>December 14, 2016</last_update_submitted>
  <last_update_submitted_qc>December 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>oral complications</keyword>
  <keyword>stage I squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage I basal cell carcinoma of the lip</keyword>
  <keyword>stage I verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage I mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage I adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II basal cell carcinoma of the lip</keyword>
  <keyword>stage II verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage II mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage II adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage I squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage I lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage II lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage I lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage II lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage II squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage I squamous cell carcinoma of the larynx</keyword>
  <keyword>stage I verrucous carcinoma of the larynx</keyword>
  <keyword>stage II squamous cell carcinoma of the larynx</keyword>
  <keyword>stage II verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage I squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

